Machine learning integrated with biology at scale lies at the core of insitro’s approach to rethinking drug discovery and development. As the Head of Production & Research Operations, you are responsible for scaling up and sustaining high-quality and efficient operations across prototyping, development and production laboratory environments. You will hire, train and manage a team of operators and technicians that support the day-to-day activities ranging from the preparation of materials for experiments, managing sample QC pipelines, and running 24/7 operations on high-throughput automation platforms. You will work closely with cross-functional teams to manage operation schedules and logistics to ensure the timely delivery of project deliverables. You will work to drive a culture of continuous improvement through innovation and implementing best practices and operational excellence initiatives. You will also work to implement validation and quality control methodologies to enable robust, reliable and reproducible results across end-to-end workflows.
You will be joining as the founding team of a biotech startup that has long-term stability due to significant funding, but yet is very much in the startup phase. Due to the early and exciting phase of growth, there are ample opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH, a collaboration with BMS in the area of ALS, and in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com
Your application was submitted successfully.